Pharma Focus Asia

Repligen

LATEST NEWSRead more...

22

Jul 2024

Everest Medicines Begins Dosing in China for Global Phase 2b Trial of Zetomipzomib for Lupus Nephritis

Everest Medicines has announced the dosing of the first Chinese patient with zetomipzomib in the global Phase b PALIZADE trial targeting active lupus nephritis Zetomipzomib

22

Jul 2024

Innovent Announces Successful Phase 3 Trial Results for Mazdutide in Type 2 Diabetes Patients in China and Plans to Submit NDA to NMPA

Innovent Biologics Inc a leading biopharmaceutical firm focusing on treatments for oncology autoimmune conditions cardiovascular diseases metabolic disorders and ophthalmology

20

Jul 2024

Shenzhen Chipscreen Biosciences Co., Ltd. Receives NMPA Approval for Chiglitazar-Metformin Combination Therapy for Type 2 Diabetes

Shenzhen Chipscreen Biosciences Co Ltd has announced that the National Medical Products Administration has granted a Drug Registration Certificate for Chiglitazar a novel

19

Jul 2024

Pluri CDMO Selected to Produce Kadimastem's Novel Cell Therapy Products

Pluri Inc a leader in biotechnology has entered into a technology transfer and manufacturing agreement with Kadimastem Ltd a clinicalstage biotechnology company focused on developing cell therapies for ALS and diabetes Through its PluriCDMO division launched earlier this year Pluri will utilize

19

Jul 2024

Phathom Pharmaceuticals Secures FDA Approval for VOQUEZNA® (vonoprazan) Tablets to Alleviate Heartburn from Non-Erosive GERD in Adults

Phathom Pharmaceuticals Inc a biopharmaceutical firm specializing in innovative treatments for gastrointestinal conditions has received FDA approval for VOQUEZNA mg tablets

19

Jul 2024

Zuellig Pharma and Institut AllergoSan Establish 10-Year Alliance to Launch OMNi-BiOTiC® Probiotics in Key Asian Markets

Zuellig Pharma a prominent healthcare solutions provider in Asia has entered into a year partnership with Institut AllergoSan an Austrian company known for its naturalbased products like probiotics plant extracts

Solovpe

press releasesRead more...

22

Jul 2024

Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia

Biophytis SA a clinicalstage biotechnology company specializing in the development of treatments for agerelated diseases today announces the deployment of its partnership

22

Jul 2024

Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy

Astellas Pharma Inc and Graduate School of Medicine Faculty of Medicine Osaka University today announced that Astellas Institute for Regenerative Medicine

20

Jul 2024

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine

Teva Pharmaceutical Industries Ltd announced today positive topline results from its Phase SPACE study evaluating the efficacy of AJOVY for the prevention of episodic migraine in children

19

Jul 2024

Analytica Vietnam 2025 Set to Be the Biggest Yet With 85% of Exhibition Halls Sold Out

The th edition of analytica Vietnam scheduled to take place from April at the Saigon Exhibition and Convention Center SECC in Ho Chi Minh City will bring together leading experts

19

Jul 2024

Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria

Nika Pharmaceuticals Inc announces the signing of a distribution agreement for the Republic of Nigeria The extensive negotiations with IConntactConnect Limited finalized on June and will allow NIKA to have a strong partner in a key market of million people

19

Jul 2024

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals Inc a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders today announced that the China National Medical Products

30 - 01

Jul 2024

30 - 01

Jul 2024

chemical indonesia

jakarta barat, Indonesia

30 - 01

Jul 2024

Inalab 2023

Jakarta Barat, Indonesia

13 - 14

Aug 2024

ADVANCING BUSINESS, TECHNOLOGY AND INNOVATION

Songdo Convensia, Incheon, South Korea

13 - 14

Aug 2024

12 YEARS OF EXCELLENCE: SOUTH KOREA’S BIOLOGICS

Songdo Convensia, Incheon, South Korea

19 - 21

Aug 2024
Hexagon - Expert Insights Webinar
MFA + MMA 2024
4th Annual Cleaning Validation 2024
2nd Annual Pharma Impurity Conclave 2024
CPHI Korea 2024
World Orphan Drug Congress Europe 2024
Thermo Fisher - Drug Discovery and the impact of mAbs

TOP ARTICLES

  • 2

    Incipient Biopharmaceutical Claims of Milk Derived Exosomes

    Rakesh Kumar Tekade

    Associate Professor, NIPER-Ahmedabad

    Nupur Vasdev

    Pursuing PhD in Pharmaceutics, NIPER-Ahmedabad

    Manisha Choudhary

    Pursuing M.S. (Pharm) in Pharmaceutics, NIPER-Ahmedabad

    Suryanarayana Polaka

    Pursuing PhD, NIPER-Ahmedabad

    Kiran Kalia

    Director and Professor, NIPER-Ahmedabad

KNOWLEDGE BANK

  • Interviews

    Thomson Reuters

    Senior Vice President

    We believe publications such as Pharmafocus Asia are essential in providing professionals with insights into the dynamic and evolving trends of the Pharma industry
  • Articles

    Artificial Intelligence in Oncology

    Cancer is the most prevalent cause of death across the globe According to the World Health Organization there is an estimated increase from the anticipated million cases of cancer in It is predicted that more than million

  • White Papers

    Halides Chemicals Pvt. Ltd. - Combining Quality And Reliability In Every Formula

    Halides Chemicals Pvt Ltd was incorporated in the year The company was formed with a view in mind to provide quality Halo Succinimides for pharmaceutical as well as chemical industry We are into manufacturing of NBromosuccinimide and NChlorosuccinimide since In the year we successfully launched NIodosuccinimide We are proudly one of very few manufacturers of NIodosuccinimide in the world ho

EDITORIAL SECTION